account_id none on file
legal_name C4 Therapeutics, Inc.
ticker CCCC
cik 1662579
domain c4therapeutics.com
linkedin_company_url https://www.linkedin.com/company/c4-therapeutics-inc./
entry_point_account_id none on file
name C4 Therapeutics Inc.
exchange Nasdaq
sector Health Care
sector index/company/sector/health-care/
calls 0 filings 8 executives 5 family 0
why_nownone on file
callsnone on file
filings
General and administrative expenses also include legal fees relating to corporate matters; professional fees for accounting, auditing, tax, and consulting services; insurance costs; travel expenses; and facility-related expenses, which include direct depreciation costs and allocated expenses for rent and maintenance of facilities and other operating costs.
filing / Aug 11, 2026 / receipt
• cost of outside consultants, including their fees and related travel expenses; • costs of laboratory supplies and acquiring materials for preclinical studies and clinical trials; • facility-related expenses, which include direct depreciation costs of equipment and allocated expenses for rent and maintenance of facilities and other operating costs; and • third-party licensing fees.
filing / Aug 11, 2026 / receipt
These increases will likely include higher costs related to the hiring of additional personnel; fees to outside consultants, lawyers and accountants; and investor and public relations costs.
filing / Aug 11, 2026 / receipt
The continuing efforts of the government, insurance companies, managed care organizations and other payors of healthcare services to contain or reduce costs of healthcare and/or impose price controls may adversely affect:
filing / Aug 11, 2026 / receipt
General and administrative expenses also include legal fees relating to corporate matters; professional fees for accounting, auditing, tax, and consulting services; insurance costs; travel expenses; and facility-related expenses, which include direct depreciation costs and allocated expenses for rent and maintenance of facilities and other operating costs.
filing / May 12, 2026 / receipt
• cost of outside consultants, including their fees and related travel expenses; • costs of laboratory supplies and acquiring materials for preclinical studies and clinical trials; • facility-related expenses, which include direct depreciation costs of equipment and allocated expenses for rent and maintenance of facilities and other operating costs; and • third-party licensing fees.
filing / May 12, 2026 / receipt
These increases will likely include higher costs related to the hiring of additional personnel; fees to outside consultants, lawyers and accountants; and investor and public relations costs.
filing / May 12, 2026 / receipt
The continuing efforts of the government, insurance companies, managed care organizations and other payors of healthcare services to contain or reduce costs of healthcare and/or impose price controls may adversely affect:
filing / May 12, 2026 / receipt
executives
| Glenn Dubin | director | - | receipt |
| Mark Mossler | Chief Accounting Officer | - | receipt |
| Ron Cooper | director | - | receipt |
| Steven L. Hoerter | director | - | receipt |
| Utpal Koppikar | director | - | receipt |
familynone on file
upcoming
| 2026-11-05 | earnings call | scheduled | ir |
changes
| 2024-11-20 | director, appointed | sec_8k |
| 2024-06-10 | director, appointed | sec_8k |
| 2023-09-05 | Chief Accounting Officer, appointed | sec_8k |
| 2022-03-16 | director, appointed | sec_8k |
| 2021-03-11 | director, appointed | sec_8k |
mcp_package_hint
slug c4-therapeutics-inc
listing_url https://steadybase.io/company/data/index.json
mcp_url https://mcp.steadybase.io/mcp
steadybase-$